1. Home
  2. EDD vs ASMB Comparison

EDD vs ASMB Comparison

Compare EDD & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

EDD

Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

HOLD

Current Price

$5.65

Market Cap

397.7M

Sector

Finance

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$29.32

Market Cap

440.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDD
ASMB
Founded
2007
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
397.7M
440.0M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
EDD
ASMB
Price
$5.65
$29.32
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$44.20
AVG Volume (30 Days)
494.8K
71.8K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.52%
N/A
EPS Growth
N/A
91.78
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$235.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.57
$9.82
52 Week High
$6.18
$39.71

Technical Indicators

Market Signals
Indicator
EDD
ASMB
Relative Strength Index (RSI) 60.55 53.18
Support Level $5.44 $29.31
Resistance Level $5.68 $30.54
Average True Range (ATR) 0.13 1.41
MACD 0.07 0.11
Stochastic Oscillator 96.62 70.11

Price Performance

Historical Comparison
EDD
ASMB

About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.

Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: